Nektar Therapeutics Webcast Conference Call for Analysts and Investors for 2020 American College of Rheumatology (ACR) Congress Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics ACR analyst call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Corporate Affairs. Ma'am, you may begin.
Thank you, Crystal. Good afternoon, everyone, and thank you for joining us on today's analyst call to review data being presented for NKTR-358 at the 2020 American College of Rheumatology Congress.
Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidate, NKTR-358, and other potential drug candidates, clinical trial results, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions and future availability of clinical trial data. Because these statements relate to the future, they are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |